Trials / Completed
CompletedNCT04896385
A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the Mechanism Of Action (MOA) of ruxolitinib cream in vitiligo by assessing the change in biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib cream | Ruxolitinib cream is a topical formulation applied as a thin film to affected areas. |
| DRUG | Vehicle Cream | Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream. |
Timeline
- Start date
- 2021-06-23
- Primary completion
- 2022-11-17
- Completion
- 2023-07-10
- First posted
- 2021-05-21
- Last updated
- 2025-08-05
- Results posted
- 2023-12-07
Locations
13 sites across 3 countries: United States, Canada, France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04896385. Inclusion in this directory is not an endorsement.